Oncolytic herpes simplex virus infects myeloma cells in vitro and in vivo

Ghose, Jayeeta; Donà, Ada; Murtadha, Mariam; Gunes, Emine Gulsen; Caserta, Enrico; Yoo, Ji Young; Russell, Luke; Jaime-Ramirez, Alena Cristina; Barwick, Benjamin G.; Gupta, Vikas A.; Sanchez, James F.; Sborov, Douglas W.; Rosen, Steven T.; Krishnan, Amrita; Boise, Lawrence H.; Kaur, Balveen; Hofmeister, Craig C.; Pichiorri, Flavia

doi:10.1016/j.omto.2021.02.009

Cited by 8 publications

(14 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Likewise, the choice of backbone would be of high interest in neuroglioma indications, as the oncolytic potential of H1052 was equal to that of its backbone (Figure S1). In the B-cell lymphoma cell line, H1052 was actually more oncolytic than 17+, despite the lower absolute replication (Figure 2), which could mean that there is high potential in oHSV treatment of hematological malignancies, as supported by recent literature [35,36].…”

Section: The Clinical Isolates Could Be Advantageous As Ohsv Backbonesmentioning

confidence: 72%

The In Vitro Replication, Spread, and Oncolytic Potential of Finnish Circulating Strains of Herpes Simplex Virus Type 1

Kalke

Orpana

Lasanen

et al. 2022

Viruses

View full text Add to dashboard Cite

Herpes simplex virus type 1 (HSV-1) is the only FDA- and EMA- approved oncolytic virus, and accordingly, many potential oncolytic HSVs (oHSV) are in clinical development. The utilized oHSV parental strains are, however, mostly based on laboratory reference strains, which may possess a compromised cytolytic capacity in contrast to circulating strains of HSV-1. Here, we assess the phenotype of thirty-six circulating HSV-1 strains from Finland to uncover their potential as oHSV backbones. First, we determined their capacity for cell-to-cell versus extracellular spread, to find strains with replication profiles favorable for each application. Second, to unfold the differences, we studied the genetic diversity of two relevant viral glycoproteins (gB/UL27, gI/US7). Third, we examined the oncolytic potential of the strains in cells representing glioma, lymphoma, and colorectal adenocarcinoma. Our results suggest that the phenotype of a circulating isolate, including the oncolytic potential, is highly related to the host cell type. Nevertheless, we identified isolates with increased oncolytic potential in comparison with the reference viruses across many or all of the studied cancer cell types. Our research emphasizes the need for careful selection of the backbone virus in early vector design, and it highlights the potential of clinical isolates as backbones in oHSV development.

show abstract

Section: The Clinical Isolates Could Be Advantageous As Ohsv Backbonesmentioning

confidence: 72%

The In Vitro Replication, Spread, and Oncolytic Potential of Finnish Circulating Strains of Herpes Simplex Virus Type 1

Kalke

Orpana

Lasanen

et al. 2022

Viruses

View full text Add to dashboard Cite

show abstract

“…Therefore, the induction of an antiviral state in potential recipient cells may hardly influence efficacy of therapy. However, the same as for wild type virus would apply in the case of replication-competent viral vectors, which may be used e.g., in oncolytic virus strategies [ 59 ]. For non-enveloped viruses, effects considered to be positive for wt virus may actually be detrimental in some cases: cloaking by EVs will hide surface characteristics and potentially change (expand) the tropism range, thus increasing off-target effects.…”

Section: Discussion—impact Of Ev-vi Interplay On Viral Vector Technologymentioning

confidence: 99%

On the Relationship of Viral Particles and Extracellular Vesicles: Implications for Viral Vector Technology

Metzner

Zaruba

2021

Viruses

View full text Add to dashboard Cite

Gene therapy vectors derived from different viral species have become a fixture in biomedicine, both for direct therapeutic intervention and as tools to facilitate cell-based therapies, such as chimeric antigen receptor-based immunotherapies. On the contrary, extracellular vesicles have only recently gained a massive increase in interest and, concomitantly, knowledge in the field has drastically risen. Viral infections and extracellular vesicle biology overlap in many ways, both with pro- and antiviral outcomes. In this review, we take a closer look at these interactions for the most prominent groups of viral vectors (Adenoviral, Adeno-associated and Retro/Lentiviral vectors) and the possible implications of these overlaps for viral vector technology and its biomedical applications.

show abstract

“…Finally, considering that HSV has an oncolytic effect on tumor cells by inducing apoptosis [ 26 , 27 ], the potential oncolytic mechanism of PRV was explored. Thus, apoptosis was examined by flow cytometry and IHC assay.…”

Section: Resultsmentioning

confidence: 99%

The Effects of Oncolytic Pseudorabies Virus Vaccine Strain Inhibited the Growth of Colorectal Cancer HCT-8 Cells In Vitro and In Vivo

Chai

Zhang

Zhou

et al. 2022

Animals

View full text Add to dashboard Cite

Oncolytic viral therapy is a promising treatment approach for a variety of tumor forms. Although a number of studies have demonstrated that the pseudorabies virus (PRV) may be applied as an oncolytic carrier, the anti-colorectal cancer impact of the virus and the mechanism of its cytotoxic effect remain elusive. In this study, the replication capacity and cell activity of PRV attenuated live vaccines Bartha K61 and HB98 in HCT-8 cells in vitro were investigated. Next, the antitumor ability and safety were evaluated in a mouse model of HCT-8 tumor transplantation. Both PRV strains were able to suppress tumor growth and HB98 showed higher safety and efficiency than the Bartha K61 strain. Finally, flow cytometry and immunohistochemistry examination were performed to investigate its possible cytotoxic mechanism. The results showed that PRV inhibited tumor proliferation both in vitro and in vivo by inducing apoptosis. In summary, our study discovered for the first time that the live attenuated PRV has an oncolytic effect on HCT-8 cells with high efficacy and safety.

show abstract

Oncolytic herpes simplex virus infects myeloma cells in vitro and in vivo

Cited by 8 publications

References 66 publications

The In Vitro Replication, Spread, and Oncolytic Potential of Finnish Circulating Strains of Herpes Simplex Virus Type 1

The In Vitro Replication, Spread, and Oncolytic Potential of Finnish Circulating Strains of Herpes Simplex Virus Type 1

On the Relationship of Viral Particles and Extracellular Vesicles: Implications for Viral Vector Technology

The Effects of Oncolytic Pseudorabies Virus Vaccine Strain Inhibited the Growth of Colorectal Cancer HCT-8 Cells In Vitro and In Vivo

Contact Info

Product

Resources

About